Citations

Showing 10 of 108094 citations.

032 The Impact of Sexual Dysfunction on Sexual Relationships
Alom, M. , Ziegelmann, M., Avant, R., Köhler, Tobias , Trost, Landon , Bole, Raevti

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S16-S16

10.1016/j.jsxm.2017.11.051 Get It

029 What about the Partner? Factors Associated with Partner Dyspareunia in Men with Peyronie's Disease
Meng, Yujie, Ziegelmann, M., Trost, Landon

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S14-S15

10.1016/j.jsxm.2017.11.048 Get It

004 Convective Radiofrequency Thermal Therapy (Rezum®) Effectively Treats Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Regardless of Obesity while Preserving Erectile and Ejaculatory Function
Köhler, Tobias , McVary, Kevin T. , Helo, Sevann , Tadros, Nicholas N. , Gupta, N.

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S2-S3

10.1016/j.jsxm.2017.11.023 Get It

National Institute on Aging – Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's disease
Siemers, Eric , Bain, Lisa J. , Hendrix, James A. , Carrillo, María C. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | February 3, 2018 | Volume: 14 | Issue: 2 | Pages: 261-262

10.1016/j.jalz.2018.01.001 | PMID 29413643 Get It

Inherited neuropathy precision classification
Klein, Christopher J.

Mayo Clinic

Neurology | February 2, 2018 | Volume: 90 | Issue: 10 | Pages: 445-446

10.1212/wnl.0000000000005077 | PMID 29429968 Get It

Sifting through a failed Alzheimer trial
Knopman, David S.

Mayo Clinic

Neurology | February 2, 2018 | Volume: 90 | Issue: 10 | Pages: 447-448

10.1212/wnl.0000000000005073 | PMID 29429973 Get It

Lingual Pressure as a Clinical Indicator of Swallowing Function in Parkinson's Disease
Pitts, Laura L. , Morales, Sarah, Stierwalt, Julie A. G.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | February 2, 2018 | Volume: 61 | Issue: 2 | Pages: 257-265

10.1044/2017_jslhr-s-17-0259 | PMID 29396576 Get It

PurposeSwallowing impairment, or dysphagia, is a known contributor to reduced quality of life, pneumonia, and mortality in Parkinson's disease (PD). However, the contribution of tongue dysfunction, specifically inadequate pressure generation, to dysphagia in PD remains unclear. Our purpose was to determine whether lingual pressures in PD are (a) reduced, (b) reflect medication state, or are (c) consistent with self-reported diet and swallowing function.MethodTwenty-eight persons with idiopathic PD (PwPD) and 28 age- and sex-matched controls completed lingual pressure tasks with the Iowa Oral Performance Instrument. PwPD were tested during practically defined ON and OFF dopaminergic medication states. Participants were also stratified into three sex- and age-matched cohorts (7 men, 5 women): (a) controls, (b) PwPD without self-reported dysphagia symptoms or diet restrictions, and (c) PwPD with self-reported dysphagia symptoms with or without diet restrictions.ResultsPwPD exhibited reduced tongue strength and used elevated proportions of tongue strength during swallowing compared with controls (p< .05) without an effect of medication state (p> .05). Reduced tongue strength distinguished PwPD with self-reported dysphagia symptoms from PwPD without reported symptoms or diet restrictions (p= .045) and controls (p= .002).ConclusionTongue strength was significantly reduced in PwPD and did not differ by medication state. Tongue strength differentiated between PwPD with and without self-reported swallowing symptoms. Therefore, measures of tongue strength and swallowing pressures may serve as clinical indicators for further dysphagia evaluation and may promote early diagnosis and management of dysphagia in PD.
Technical Note: An efficient daily QA procedure for proton pencil beam scanning
Younkin, James E. , Shen, Jiajian , Robertson, Daniel , Mundy, Daniel W. , Clouser, Edward , Ding, Xiaoning, Stoker, Joshua B., Bues, Martin , Robertson, Daniel G, Shen, Jiajian , Liu, Wei , Clouser, Edward Lee

Mayo Clinic

Medical Physics | February 2, 2018 | Volume: 45 | Issue: 3 | Pages: 1040-1049

10.1002/mp.12787 | PMID 29394447 Get It

PurposeThe aim of this work was to develop an efficient daily quality assurance (QA) program with strict tolerance levels for pencil beam scanning (PBS) proton radiotherapy featuring simultaneous dosimetric testing on a single, nonuniform field.MethodsA nonuniform field measuring beam output, proton range, and spot position was designed for delivery onto a Sun Nuclear Daily‐QA 3 device. A custom acrylic block permitted simultaneous measurement of low‐ and high‐energy proton ranges in addition to beam output. Sensitivities to output, range, and spot position were evaluated to quantitate the device's response. Reproducibility tests were used to identify and control sources of measurement error as well as to assess the QA procedure's robustness. This procedure was implemented in each of our four treatment rooms independently; 4–6 months of daily QA measurements were collected.ResultsThe 1% output, 0.5 mm range, and 1.5 mm spot position tolerances derived from preliminary tests were tighter overall than tolerances found in the literature and equivalent to the limits used for proton system commissioning. The simplicity and automation of the procedure reduced the time required for daily QA to 10 min per treatment room, and competition for beam between multiple treatment rooms was minimized.ConclusionsAn efficient daily PBS QA procedure can be performed using a single, nonuniform field on a nondedicated QA device. A thorough quantitation of the device's response and careful control of measurement uncertainties allowed daily tolerances to match commissioning standards.
Role of a Standardized Prism Under Cover Test in the Assessment of Dissociated Vertical Deviation
Klaehn, Lindsay D. , Leske, David A. , Holmes, Jonathan M. , Hatt, Sarah R. , Holmes, Jonathan M.

Mayo Clinic

Strabismus | February 2, 2018 | Volume: 26 | Issue: 1 | Pages: 1-5

10.1080/09273972.2017.1391850 | PMID 29393712 Get It

Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner
Osman, Abu , Gurish, Michael F. , Dennis, Kristen L., Blatner, Nichole R., Pezeshki, Abdulmohammad , McNagny, Kelly M. , Cheroutre, Hilde , Gounari, Fotini , Khazaie, Khashayarsha , Saadalla, Abdulrahman M, McNagny, Kelly M , Khazaie, Khashayarsha , Saadalla, Abdulrahman , Gounari, Fotini

Mayo Clinic

Proceedings of the National Academy of Sciences | February 2, 2018 | Volume: 115 | Issue: 7 | Pages: 1588-1592

10.1073/pnas.1716804115 | PMID 29429965 Get It

Significance We show that distinct subsets of mast cells (MCs) expand with sequential oncogenic events in small bowel cancer. Mucosal mast cells (MMCs) previously detected early during Trichinella spiralis infection expand in adenomatous polyps in an IL-10–dependent manner. Connective tissue mast cells (CTMCs), earlier shown to expand during the resolution of inflammation following clearance of T. spiralis, are independent of IL-10 and associate with the transition of polyps to adenocarcinoma. IL-33 upregulates the CTMC lineage-specific protease murine mast cell protease 6 (mMCP6). Ablation of mMCP6 attenuates tumor growth. Thus, tissue sentinel cells respond to oncogenic events and cellular transformation in effect to help promote cancer. Delineating the types of MCs present at various stages of disease offers actionable cellular targets for therapeutic intervention in disease progression.